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ABSTRACT 
 
Buccal drug delivery is a promising area for continued research with the aim of systemic delivery of 
orally inefficient drugs as well as a feasible and attractive alternative for non-invasive delivery of 
potent peptide and protein drug molecules. However, the need for safe and effective buccal permeation 
absorption enhancers is a crucial component for a prospective future in the area of buccal drug 
delivery. Buccal nitroglycerin, can use for acute therapy for an animal attack as well as for chronic 
prophylaxis Novel liquid aerosol formulation of insulin Development of suitable delivery devices, 
permeation enhancement, and Buccal delivery of drugs that undergo a first-pass effect, such as 
cardiovascular drugs, analgesics, and peptides Research yield some successes Promote further research; 
more companies Rest depend on delivery technology  
 
Key word : Buccal, first-pass effect, suitable delivery devices, permeation enhancement. 
 
INTRODUCTION 
Amongst the various routes of drug delivery, oral route is perhaps the most preferred to the patient and 
the clinician alike. However, administration of drugs has disadvantages such as hepatic first pass 
metabolism and enzymatic degradation within the GI tract, that prohibit oral administration of certain 
classes of drugs especially peptides and proteins.  
The nasal cavity as a site for systemic drug delivery has been investigated by many research groups
1-7 
and the route has already reached commercial status with several drugs including LHRH 
8-9
  and 
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However, the potential irritation and the irreversible damage to the ciliary action of the 
nasal cavity from chronic application of nasal dosage forms, as well as the large intra- and inter-subject 
variability in mucus secretion in the nasal mucosa, could significantly affect drug absorption from this 
site. Even though the rectal, vaginal, and ocular mucosa all offer certain advantages, the poor patient 
acceptability associated with these sites renders them reserved for local applications rather than 
systemic drug administration.. These factors make the oral mucosal cavity a very attractive and feasible 
site for systemic drug delivery. Within the oral mucosal cavity, delivery of drugs is classified into three 
categories: (i) sublingual delivery, which is systemic delivery of drugs through the mucosal membranes 
lining the floor of the mouth, (ii) buccal delivery, which is drug administration through the mucosal 






1.1) ADVANTAGES OF BUCCAL DRUG DELIVERY
13-17
 
1. Bypass of the gastrointestinal tract and hepatic portal system, increasing the bioavailability of orally 
administered drugs that otherwise undergo hepatic first-pass metabolism. In addition the drug is 
protected from degradation due to pH and digestive enzymes of the middle gastrointestinal tract  
2. Improved patient compliance due to the elimination of associated pain with injections;  
3. A relatively rapid onset of action can be achieved relative to the oral route, and the formulation can 
be removed if therapy is required to be discontinued.  
4. Increased ease of drug administration  
5. Though less permeable than the sublingual area, the buccal mucosa is well vascularized, and drugs 
can be rapidly absorbed into the venous system underneath the oral mucosa.  
6. In comparison to TDDS, mucosal surfaces do not have a stratum corneum. Thus, the major barrier 
layer to transdermal drug delivery is not a factor in transmucosal routes of administration. 
 
 
                      
 
1.2) OVERVIEW OF THE ORAL MUCOSA 
 
A. Structure 
    The oral mucosa is composed of outermost layer of stratified epithelium.Below lies a basement 
membrane, a lamina prairie followed by the submucosa as the innermost layer. The epithelium is 
similar to stratified squamous epithelia found in the rest of the body in that it has a mitotically active 
basal cell layer, advancing through a number of differentiating intermediate layers to the superficial 
layers, where cells are shed from the surface of the epithelium
18.
 The epithelium of the buccal mucosa 
is about 40-50 cell layers thick, while that of the sublingual epithelium contains somewhat fewer. The 
epithelial cells increase in size and become flatter as they travel from the basal layers to the superficial 
layers. The turnover time for the buccal epithelium.It has been estimated at 5-6 days
2
, and this is 
probably representative of the oral mucosa as a whole. The oral mucosal thickness varies depending on 
the site: the buccal mucosa measures at 500-800 µm, while the mucosal thickness of the hard and soft 
palates, the floor of the mouth, the ventral tongue, and the gingival measure at about 100-200 µm.  
 
 
B. Role of Saliva  
 Protective fluid for all tissues of the oral cavity.  
 Continuous mineralization / demineralization of the tooth enamel.  
 To hydrate oral mucosal dosage forms.  
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C. Role of Mucus  
 Made up of proteins and carbohydrates.  
 Made up of proteins and carbohydrates.  
 Cell-cell adhesion  
 Lubrication  
 Bioadhesion of mucoadhesive drug delivery systems  
D. Permeability 
 
 The oral mucosa in general is somewhat leaky epithelia intermediate between that of the epidermis and 
intestinal mucosa. It is estimated that the permeability of the buccal mucosa is 4-4000 times greater 
than that of the skin
20
 In general, the perm abilities of the oral mucosa decrease in the order of 
sublingual greater than buccal, and buccal greater than palatal. This rank order is based on the relative 
thickness and degree of keratinization of these tissues, with the sublingual mucosa being relatively thin 
and non-keratinized, the buccal thicker and non-keratinized, and the palatal intermediate in thickness 
but keratinized.   
E. Structure And Design Of Buccal Dosage Form 
23 
1. Matrix type: The buccal patch designed in a matrix configuration contains drug, adhesive, and 
additives mixed together  
 
2. Reserviour type: The buccal patch designed in a reservoir system contains a cavity for the drug and 
additives separate from the adhesive. An impermeable backing is applied to control the direction of 









F. Permeability Of Drugs Through Buccal Mucosa 
24 
There are two possible routes of drug absorption through the squamous stratified epithelium of the oral 
mucosa:  
 
i.Transcellular (intracellular, passing through the cell)  
 
ii.Paracellular (intercellular, passing around the cell).  
 
Permeation across the buccal mucosa has been reported to be mainly by the Para cellular route through 
the intercellular lipids produced by membrane-coating granules.  
 




In the development of these buccal drug delivery systems, mucoadhesion of the device is a key 
element. The term ‘mucoadhesive’ is commonly used for materials that bind to the mucin layer of a 
biological membrane These dosage forms include tablets, patches, tapes, films, semisolids and 
powders. To serve as mucoadhesive polymers, the polymers should possess some general 
physiochemical features such as  
 
1. Predominantly anionic hydrophilicity with numerous hydrogen bond-forming groups  
Innovative Systems Design and Engineering   www.iiste.org 
ISSN 2222-1727 (Paper) ISSN 2222-2871 (Online) 




2. Suitable surface property for wetting mucus/mucosal tissue surfaces and  
 
H. Factors Affecting Drug Delivery via Buccal Route 
26
 
The rate of absorption of hydrophilic compounds is a function of the molecular size. Smaller molecules 
(75-100 Da) generally exhibit rapid transport across the mucosa, with permeability decreasing as 
molecular size increases. For hydrophilic macromolecules such as peptides, absorption enhancers have 
been used to successfully alter the permeability of the buccal epithelium, causing this route to be more 
suitable for the delivery of larger molecules.  
 
 
I. Toxicity And Irritancy Associated With Buccal Drug Delivery
27
 
Formulations that produce local damage at the site of application, such as ulceration of the mucosa, 
would preclude their widespread usage as a result of the associated pain and discomfort. This is 
articularly important in buccal drug delivery where the formulation is in contact with the mucosa for 
extended periods. Toxic effects can arise from the drug itself, the bioadhesive or from other 
components of the formulation 
J. Methods to Increase Drug Delivery via Buccal Route 
(1) Absorption enhancers 
26 
Absorption enhancers have demonstrated their effectiveness in delivering high molecular weight 
compounds, such as peptides, that generally exhibit low buccal absorption rates.  
 
Sr. no  Permeation Enhancers  Sr. no  Permeation Enhancers  
1  2,3-Lauryl ether    9 Phosphatidylcholine  
2  Aprotinin   10  Polyoxyethylene  
3  Azone   11  Polysorbate 80  
4  Benzalkonium chloride   12  Polyoxyethylene  
5  Cetylpyridinium chloride   13 Phosphatidylcholine  
6  Cetyltrimethyl ammonium bromide   14  Sodium EDTA  
7  Cyclodextrin   15  Sodium glycocholate  
8  Dextran sulfate   16  Sodium glycodeoxycholate  
 








Hussein et al delivered opioid agonists and antagonists in bitterness prodrug forms and found that the 
drug exhibited low bioavailability as prodrug.  
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Nalbuphine and naloxone bitter drugs when administered to dogs via the buccal mucosa, the caused 




Shojaei et al evaluated permeability of acyclovir at pH ranges of 3.3 to 8.8, and in the presence of the 
absorption enhancer, sodium glycocholate. The in vitro permeability of acyclovir was found to be pH 
dependent with an increase in flux and permeability coefficient at both pH extremes (pH 3.3 and 8.8), 
as compared to the mid-range values (pH 4.1, 5.8, and 7.0).  
 
(4) Patch design 
26
 
Several in vitro studies have been conducted regarding on the type and amount of backing materials 
and the drug release profile and it showed that both are interrelated. 




1.3) CLASSIFICATION OF BUCCAL BIOADHESIVE DOSAGE FORMS 
 
1. Buccal Bioadhesive Tablets. 
2. Buccal Bioadhesive semisolids 
3. Buccal Bioadhesive patch and films 
4. Buccal Bioadhesive Powders 
 
BUCCAL BIOADHESIVE TABLETS 
Buccal bioadhesive tablets are dry dosage forms that are to be moistened prior to placing in contact 
with buccal mucosa. Double and multilayered tablets are already formulated using bioadhesive 
polymers and excipients. The two buccal bioadhesive tablets commercially available buccoadhcsive 
tablets in UK are "Bucastem" and” Suscard buccaP'. 
 
BUCCAL BIOADHESIVC SEMISOLID DOSAGE FORMS 
 
Buccal bioadhesive semisolid dosage forms consists of 
finally powdered natural or synthetic polymer dispersed in a polyethylene or in aqueous solution, 
Example: Arabase.21 
 
BUCCAL BIOADHESIVE PATCHES AND FILMS 
Buccal bioadhesive patches consists of two ply laminates or multilayered thin film round or oval as 
consisting of basically of bioadhesive polymeric layer and impermeable backing layer to provide 
unidirectional flow of drug across buccal mucosa. Buccal bioadhesive films arc formulated by 
incorporating the drug in alcohol solution of bioadhesive polymer. 
 
BUCCAL BIOADHESIVE POWDER DOSAGE FORMS 
 
Buccal bioadhesive powder dosage forms are a mixture of Bioadhesive polymers and the drug and are 
sprayed onto the buccal mucosa the reduction in diastolic B.P after the administration of buccal tablet 






1.4)  BASIC COMPONENTS OF BUCCAL BIOADHESIVE DRUG DELIVERY SYSTEM 
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The basic components of buccal bioadhesive drug delivery system are 
 Drug substance 
 Bioadhesive polymers 
 Backing membrane 
 Penetration enhancers 
 Adhesives 
1. DRUG SUBSTANCE 
 
Before formulating buccoadhcsive drug delivery systems, one has to decide whether the intended, 





1. The conventional single dose of the drug should be small. 
    The drugs having biological half-life between 2-8 hours are good candidates     for controlled drug 
delivery. 
 
2. Tmax of the drug shows wider-fluctuations or higher values when given orally.
30
 
     
3. The drug absorption should be passive when given orally. 
 
 2. BIOADHESIVE POLYMERS 
 
  
The first step in the development of buccoadhcsive dosage forms is the selection and characterization 
of appropriate bioadhesive polymers in the formulation." Bioadhesive polymers play a major role in 
buccoadhcsive drug delivery systems of drugs. Polymers arc also used in matrix devices in which the 
drug is embedded in the polymer matrix, which controls the duration of release of drugs An ideal 
polymer for buccoadhcsive drug delivery systems should have following Characteristics. 
 
1. It should be inert and compatible with the environment 
2. The polymer and its degradation products should be non-toxic absorbable from the  
    Mucous layer. 
3. It should adhere quickly to moist tissue surface and should possess some site  
    Specificity. 
4. The polymer must not decompose on storage or during the shelf life of the dosage  
   form. 
5. The polymer should be easily available in the market and economical. 
 
Criteria followed in polymer selection 
 
 It should form a strong non covalent bond with the mucin/epithclial surface  
 It must have high molecular weight and narrow distribution. 
 It should be compatible with the biological membrane. 
 The polymers that are commonly used as bioadhesive in pharmaceutical applications are: 
   1. Natural polymers 
    Ex.: Gelatin, sodium alginate. 
   2. Synthetic and scmisynthctic polymers 
    Ex.: PVA, PEG, HPMC, PVP, carbomers etc
31 
1. BACKING MEMBRANE 
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Backing membrane plays a major role in the attachment of bioadhesive devices to the mucus 
membrane. The materials used as backing membrane should be inert, and impermeable to the 
drug and penetration enhancer.The commonly used materials in backing membrane include 
carbopol, magnesium separate, HPMC, HPC, CMC, polycarbophil etc. 
 
4. PENETRATION ENHANCERS 
 
Penetration enhancers arc used in buccoadhcsive formulations to improve the release of the drug. They 









Bioadhesive are the substances that are capable of interacting with the biological material and being 
retained on them or holding them together for extended period of time.Bioadhesive can be used to 
apply to any mucous or no mucous membranes and it also increases intimacy and duration of contact of 
the drug with the absorbing membrane. The commonly used bioadhesive are sodium alginate, 
carbomers, polycarbophil, HPMC, HPC, gelatin etc. 
 
The bioadhesive should have the following characters, 
 
1. It should not produce any residue on mucosa layer. 
2. It should be inert and compatible with biological environment. 
3. It should adhere to the mucus membrane aggressively 
4. It should preferably form a strong non-covalent bond with mucin/ epithelial ceil  
    Surface. 
 
 
1.5) LIST OF DRUGS DELIVERED VIA BUCCAL ROUTE 33 
 
In an effort to determine the feasibility of buccal route as a novel route of drug delivery, several drugs 
have been studied. The variation in class of compounds illustrates that the pharmaceutical industries 
have an alternative and novel routes of administration for existing drugs.  
 
Sr. No.  Active Ingredients Sr. No. Active Ingredients 
1.  Acitretin 19 Metronidazole 
2 Acyclovir 20 Melatonin 
3 Arecoline 21 Metoprolol tartrate 
4 Buprenorpine 22 Morphine sulphate 
5 Carbamazepine 23 Nalbuphine 
6 Cetyl Pyridinium chloride 24 Nicotine 
7 Chlorhexidine diacetate 25 Nifedipine 
8 Chitosan 26 Omeprazole 
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9 Chlorpheniramine maleate 27 Oxytocin 
10 Cyanocobalamin 28 Pentazocine 
11 Danazol 29 Protirelin 
12 Denbufylline 30 Pindolol 
13 Diclofenac sodium 31 Piroxicam 
14 Diltiazem Hydrochloride 32 Propranolol 
15 Ergotamine tartrate 33 Propolis 
16 Fluride 34 Recombinant human epidermal growth factor (Rh EFG) 
17 Flurbiprofen 35 Salmon calcitonin 
18 Glucagon-like peptide (GLP)-1 36 Sodium fluoride 
         
 
 
1.6) LIMITATIONS OF BUCCAL DRUG DELIVERY 34-37 
 
Depending on whether local or systemic action is required the challenges faced while delivering drug 
via buccal drug delivery can be enumerated as follows.  
 
1. For local action the rapid elimination of drugs due to the flushing action of saliva or the ingestion of 
foods stuffs may lead to the requirement for frequent dosing. 
  
2. The non-uniform distribution of drugs within saliva on release from a solid or                                                                     
semisolid delivery system could mean that some areas of the oral cavity may not receive effective 
levels 
 
.3.For both local and systemic action, patient acceptability in terms of taste, irritancy and ‘mouth feel’ 
is an issue.  
 
            
 
1.7) BUCCAL ROUTES OF DRUG ABSORPTION 
 
 
The are two permeation pathways for passive drug transport across the oral mucosa: Para cellular and 
Tran cellular routes. Permeates can use these two routes simultaneously, but one route is usually 
preferred over the other depending on the physicochemical properties of the diffusion. Since the 
intercellular spaces and cytoplasm are hydrophilic in character, lipophilic compounds would have low 
solubility’s in this environment. The cell membrane, however, is rather lipophilic in nature and 
hydrophilic solutes will have difficulty permeating through the cell membrane due to a low partition 
coefficient. Therefore, the intercellular spaces pose as the major barrier to permeation of lipophilic 
compounds and the cell membrane acts as the major transport barrier for hydrophilic compounds. Since 
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2.1) EXPERIMENTAL METHODOLOGY FOR BUCCAL PERMEATION STUDIES 
 
Before a buccal drug delivery system can be formulated; buccal absorption/permeation studies must be 
conducted to determine the feasibility of this route of administration for the candidate drug. These 
studies involve methods that would examine in vitro and/or in vivo buccal permeation profile and 
absorption kinetics of the drug.  
 
A. In vitro Methods 
At the present time, most of the in vitro studies examining drug transport across buccal mucosa have 
used buccal tissues from animal models. Animals are sacrificed immediately before the start of an 
experiment. Buccal mucosa with underlying connective tissue is surgically removed from the oral 
cavity, the connective tissue is then carefully removed and the buccal mucosal membrane is isolated. 
The membranes are then placed and stored in ice-cold (4°C) buffers (usually Krebs buffer) until 
mounted between side-by-side diffusion cells for the in vitro permeation experiments 
 
B. In vivo Methods 
In vivo methods were first originated by Beckett and Triggs with the so-called buccal absorption test. 
Using this method, the kinetics of drug absorption was measured. The methodology involves the 
swirling of a 25 ml sample of the test solution for up to 15 minutes by human volunteers followed by 
the expulsion of the solution. The amount of drug remaining in the expelled volume is then determined 
in order to assess the amount of drug absorbed. Various modifications of the buccal absorption test 
have been carried out correcting for salivary dilution and accidental swallowing, but these 
modifications also suffer from the inability of site localization.  
 
C. Experimental Animal Species 
 
Aside from the specific methodology employed to study buccal drug absorption/permeation 
characteristics, special attention is warranted to the choice of experimental animal species for such 
experiments. For in vivo investigations, many researchers have used small animals including rats and 
hamsters) or permeability studies.  
 
2.2) DEVELOPMENT & IN VlTRO EVALUATION TASTE MASKED BUCCAL DOSAGE FORM OF 
AN ANTIMIGRAINE AGENT 
Introduction 
Taste masked buccal dosage form of Sumatriptan_Succinate (SS) was prepared by wet granulation 
method. Initially placebo buccal tablets were prepared by using combination of various bioadhesive 
polymers and normal tablet excipients & optimized on the basis of bioadhesive strength. Various taste 
masking trials were carried out and finally taste masking was done by complexation with ion - 
exchange resin. Drug - resin complex was then loaded in the optimized formulations. The final 
formulation was optimized on the basis of pharmacopoeial tablet tests, bioadhesive strength & in-vitro 
release studies. 
 
 1.  Development of Placebo buccal tablets - Placebo buccal tablets were     prepared by wet granulation 
method; using PVP K 30 as binder 
 
2. Taste masking of the drug - It was done by completion with ion - exchange     resin. Complex 
formation was confirmed by FT-IR spectroscopy  
 & DSC studies. 
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3.  Development of drug loaded tablets - Taste masked complex was loaded in     the optimized placebo 
tablet and these tablets evaluated for pharmacopoeial Tablet tests bioadhesive strength & in-vitro 
release studies. 
                                     




2.3)  RECENT & FUTURE OF BDDS: 
  
Buccal nitroglycerin, can use for acute therapy for an animal attack as well as for chronic prophylaxis 
Novel liquid aerosol formulation of insulin Development of suitable delivery devices, permeation 
enhancement, and Buccal delivery of drugs that undergo a first-pass effect, such as cardiovascular 
drugs, analgesics, and peptides Research yield some successes Promote further research; more 
companies Rest depend on delivery technology  
                                                    
 
 
  2.4) CONCLUSION 
 
 
The buccal mucosa offers several advantages over controlled drug delivery for extended periods of 
time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism 
in the liver and pre-systemic elimination in the gastrointestinal tract are avoided. The area is well suited 
for a retentive device and appears to be acceptable to the patient. With the right dosage form design and 
formulation, the permeability and the local environment of the mucosa can be controlled and 
manipulated in order to accommodate drug permeation. Buccal drug delivery is a promising area for 
continued research with the aim of systemic delivery of orally inefficient drugs as well as a feasible and 
attractive alternative for non-invasive delivery of potent peptide and protein drug molecules. However, 
the need for safe and effective buccal permeation absorption enhancers is a crucial component for a 
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